Just two drugmakers left bidding for Sanofi's European generics business

6 February 2018

It has emerged that the number of industry players in the running to buy Sanofi’s (Euronext: SAN) European generics business Zentiva has been whittled down to two.

Reuters reports that Brazilian drugmaker EMS and Indian firm Torrent Pharma are competing for the business, which is thought to be worth up to $2.5 billion.

Sanofi reportedly wants to wrap up the process in the next couple of months, and it’s expected that bidding between the drugmakers, which are up against a number of investment funds, could drive the price up further.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Generics